Lederman M M, Schiffman G, Rodman H M
Diabetes. 1981 Feb;30(2):119-21. doi: 10.2337/diab.30.2.119.
The antibody responses of 102 adult insulin-treated diabetics who received 14-valent pneumococcal polysaccharide vaccine were measured. Grand mean preimmunization antibody levels were similar for diabetics, 255 ng protein N/ml, and controls, 234 ng protein N/ml. Postimmunization, the values in the diabetics, 1009 ng protein N/ml, and 834 ng protein N/ml in 48 healthy controls, were not significantly different. The height of antibody response in the diabetic group did not correlate with age, sex, duration of diabetes, insulin dose, concentration of glycosylated hemoglobin, fasting or 2-h postprandial glucose concentrations, or the presence of retinopathy. Side effects were minimal and occurred in 26%. Antibody response to pneumococcal polysaccharide vaccine is not impaired in adult diabetics. Pneumococcal immunization is safe and may reduce the frequency of pneumonia and its complications in the diabetic population.
对102名接受14价肺炎球菌多糖疫苗的成年胰岛素治疗糖尿病患者的抗体反应进行了测量。糖尿病患者免疫前抗体水平的总体平均值为255 ng蛋白N/ml,与对照组(234 ng蛋白N/ml)相似。免疫后,糖尿病患者的值为1009 ng蛋白N/ml,48名健康对照者的值为834 ng蛋白N/ml,两者无显著差异。糖尿病组抗体反应的高度与年龄、性别、糖尿病病程、胰岛素剂量、糖化血红蛋白浓度、空腹或餐后2小时血糖浓度或视网膜病变的存在无关。副作用轻微,发生率为26%。成年糖尿病患者对肺炎球菌多糖疫苗的抗体反应未受损。肺炎球菌免疫是安全的,可能会降低糖尿病患者肺炎及其并发症的发生率。